# A miniature low-immunogenic platform for the biosynthesis of self-assembling protein nanoparticles

## TL;DR

Researchers created a low-immunogenic platform for making self-assembling protein nanoparticles that could be used for vaccines or drug delivery.

## Contribution

A new miniature platform using a 30-amino acid peptide replaces a previously used immunogenic protein.

## Key findings

- The pepA1-based platform achieved 100% seroconversion rate in mice.
- The platform showed low immunogenicity without the need for adjuvants.
- Improved synthesis and purification procedures enhance its potential for vaccine development.

## Abstract

Aims: Previously, to obtain antigen-presenting self-assembling protein nanoparticles (SAPN), we developed a biosynthetic platform combining the self-associating peptide L6KD and the SUMO protein. In the current work, the immunogenic SUMO was replaced with an artificial 30 amino acid long peptide pepA1.

Methods: The immunogenic properties of the pepA1-SAPN were tested in mice using the pneumococcal PhtD19 and ovalbumin OVA257-280 antigens in the absence of adjuvants.

Results and Conclusions: The updated SAPN showed a 100% seroconversion rate and low immunogenicity of the platform. Given the effective synthesis and improved purification procedure, the pepA1-based miniature platform looks promising for development of vaccines and vehicles for targeted delivery.